From ESC: Remote Monitoring for Atrial Fibrillation, Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction, RSV Vaccine to Prevent Hospitalizations in Older Adults, and more

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2025 European Society of Cardiology Congress. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, with JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS.

Related Content:

• Remote Screening for Asymptomatic Atrial Fibrillation
• Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation
• Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock
• Helicobacter pylori Screening After Acute Myocardial Infarction
• Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction
• Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease
• Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk
• Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
• Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults
• High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults
• Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine
• Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis
• Participation of Women in Cardiovascular Trials From 2017 to 2023
• Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region